UK: +44 (0) 1283 753 220
US: +1 908 829 4146
Bionical Group’s recent acquisition of US business McCallan Health* marks a key realization for both companies.
Based in the UK, this acquisition will not only increase Bionical’s global reach, support and expertise, but McCallan’s established US base and distribution channels will markedly enhance and advance Bionical’s US capability.
Bionical Group CEO Graham McIntosh said: “Bionical’s core Clinical Trial Services division has shown phenomenal growth this year, exceeding all expectations. However, although organic growth is a must, this acquisition is the first of several as we continue our strategy of becoming the number one Specialist Pharmaceutical Services organisation".
The US arm of the new Bionical Group expects to move to new purpose built corporate headquarters in central New Jersey in February. All current McCallan staff will be retained and the US businesses will be integrated under McCallan’s current CEO Andy Woolf, who will become CEO of Bionical Inc, reporting directly to the main board of the Bionical Group. Bionical and McCallan pride themselves on their supreme client service and quality. These elements will continue, but with added range and depth, meaning existing Bionical and McCallan clients can only benefit from this exciting development.
This announcement coincides with another significant, strategic acquisition as Bionical also recently acquired North 51, a Nottingham-based healthcare company specialising in recruitment and contract sales.
*McCallan’s innovative products include its engagement platforms such as MED Select™. These platforms have already been used by over 10,000 US pharmaceutical representatives delivering extended periods of quality engagement and interactions with over a quarter of a million US physicians since launch.
All rights reserved © 2019 Bionical Ltd.